Inhaled Iloprost for Suspected COVID-19 Respiratory Failure

COVID-19 Clinical Trial

— ILOCOVID  

Official title:

Inhaled Iloprost for the Treatment of Suspected COVID-19 Respiratory Failure

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04445246
• Other study ID #: MRC-05-026
• Status: Completed
• Phase: Phase 2
• Start date: May 23, 2020
• Est. completion date: May 31, 2021

Study information

• Verified date: May 2020
• Source: Hamad Medical Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Acute respiratory distress syndrome (ARDS) is a type of respiratory failure characterized by the rapid onset of widespread inflammation in the lungs. ARDS is thought to be the main cause of respiratory failure in COVID-19 patients. Research is still ongoing to further elucidate the different ARDS subtypes that may exist in COVID-19. It is crucial to find new targets for treatment and support of COVID-19 patients with respiratory failure.

Description:

The investigators hypothesize that inhaled prostacyclins (Iloprost in this study) may improve inflammation and oxygenation in suspected or confirmed COVID-19 patients with respiratory failure. Research participants: Suspected or confirmed COVID-19 patients presenting to the emergency department (ED) of intensive care units (ICU) with Hypoxemic respiratory failure. Intervention: Inhaled Iloprost (Tradename Ventavis by Actelion Pharmaceuticals US, Inc.) three times daily for 5 days Methods: patients will be screened in ED and ICU for inclusion and exclusion criteria and then consent will be obtained. The intervention will be started within 48 hours of presentation. Baseline parameters on oxygenation, inflammatory markers, hemodynamics will be obtained and followed serially over the period of the intervention. Additional data about time to intubation, time on mechanical ventilation, lung mechanics, and need for prone positioning will also be collected. Data will be analyzed for percentage improvement in oxygenation (Oxygen saturation and PaO2/FiO2 ratio), trends of inflammatory markers, and hemodynamic stability while Iloprost is administered. Based on previous studies of Iloprost on ARDS patients, the investigators anticipate an improvement in oxygenation and inflammatory parameters and possible prevention of intubation with shorter mechanical ventilation times. Iloprost showed a safe profile with stable hemodynamics during administration.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: May 31, 2021
• Est. primary completion date: May 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Suspected or confirmed COVID-19 patient by PCR

2. O2 saturation =<92% on 5 or more l/min of O2 by NC or Face mask

3. On CPAP, HFNC or Invasive ventilation

4. Enrollment within 48h of onset of hypoxemia

Exclusion Criteria:

1. Age <18

2. Pregnancy or Positive pregnancy test at the time of screening

3. Clinical evidence of left atrial hypertension or known chronic CHF

4. Persistent Hypotension SBP<85 on presentation

5. Mechanical ventilation >7 days

6. Patients who received iloprost treatment for any indication within 48 hours prior to enrollment in the clinical trial or patients who were on thrombin inhibitors, or nitric oxide within the previous 24 h before study randomization are also excluded.

7. Patients with contraindication for ilioprost

Related Conditions & MeSH terms

• ARDS, Human
• COVID-19
• Hypoxemic Respiratory Failure
• Respiratory Distress Syndrome
• Respiratory Insufficiency

Intervention

Drug:
• Inhaled ILOPROST
Inhaled Iloprost 20 mcg every 8 hours for 5 days only delivered by nebulization.

Locations

Country	Name	City	State
Qatar	Hamad Medical Corporation	Doha

Sponsors (1)

Lead Sponsor	Collaborator
Hamad Medical Corporation

Country where clinical trial is conducted

Qatar, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	change in oxygenation parameters	change in oxygen saturation and PaO2/FiO2 ratio by 20% on day 6 compared to baseline values prior to Iloprost initiation.	5 days
Secondary	Rates of endotracheal intubation	likelihood to require intubation in the cohort treated with Iloprost	28 days
Secondary	Invasive ventilation duration	in days in the cohort treated with Iloprost	28 days
Secondary	ICU length of stay	in days in the cohort treated with Iloprost	28 days
Secondary	Hospital Length of stay	in days in the cohort treated with Iloprost	28 days
Secondary	Rates of proning therapy	likelihood to require proning in the cohort treated with Iloprost	28 days
Secondary	Rates of ECMO cannulation	likelihood to require ECMO cannulation in the cohort treated with Iloprost	28 days
Secondary	Mortality	likelihood to die of any cause within 28 days of initial hospital presentation	28 days